Hyperspectral Imaging: Identification of the intersegmental plane
Study summary
The purpose of this study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Histologically confirmed lung cancer stage I/II or malignancy suspicious nodules
2. Segmentectomy is oncologically indicated or impaired pulmonary and/or cardiac function prevent anatomical resection
3. Male or female patients aged ≥ 18 years without upper age limit
4. Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance (CrCl ≥ 50 mL/min, Cockcroft-Gault formula)
5. Total bilirubin ≤ 1.5 x upper limit of normal (except patients with Gilbert Syndrome (Morbus Meulengracht) in whom total bilirubin \< 3.0 mg/dL is allowed)
6. Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase)/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase) ≤ 2.5 x upper limit of normal
7. Full legal capacity
8. Written informed consent obtained according to international guidelines and local laws
9. Ability to understand the nature of the trial and the trial related procedures and to comply with them
Exclusion Criteria:
1. Requirement of a lobectomy or pneumonectomy to achieve complete resection
2. Allergy to indocyanine green or iodine
3. Hyperthyroidism
4. Current or planned pregnancy, nursing period (if defined as requirement of clinical routine treatment)
5. Medical condition which poses a high risk to undergo surgery as defined by the investigator
6. Covid19 / SARS-CoV2-infection at time of screening
7. Participation in any other interventional clinical trial within the last 30 days before the start of this trial
8. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed
9. Known or persistent abuse of medication, drugs or alcohol
10. Person who is in a relationship of dependence/employment with the coordinating investigator or the investigator
Primary outcome measure(s)
Intersegmental Plane identification — directly before pulmonary intersegmental plane dissection Distance between intersegmental plane identification with Hyperspectral Imaging compared to near-infrared indocyanine green fluorescence
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.